Incretin-based therapy of metabolic disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new agents will radically change our approach to the treatment of T2DM and obesity alike.
Originalsprog | Engelsk |
---|---|
Artikelnummer | A10220597 |
Tidsskrift | Danish Medical Journal |
Vol/bind | 70 |
Udgave nummer | 1 |
ISSN | 2245-1919 |
Status | Udgivet - 2023 |
Bibliografisk note
Publisher Copyright:
© 2023, Almindelige Danske Laegeforening. All rights reserved.
Links
- https://ugeskriftet.dk/dmj/incretin-based-therapy-metabolic-disease
Forlagets udgivne version
ID: 340118796